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Abstract
Objectives To compare MR imaging with or without DWI and clinical response evaluation (CRE) in the local control evaluation
of cervical carcinoma after radiotherapy.
Methods In a multicentre university setting, we prospectively included 107 patients with primary cervical cancer treated with
radiotherapy. Sensitivity and specificity for CRE and MR imaging (with pre-therapy MR imaging as reference) (2 readers) were
evaluated using cautious and strict criteria for identifying residual tumour. Nested logistic regressionmodels were constructed for
CRE, subsequently adding MR imaging with and without DWI as independent variables, as well as the pre- to post-treatment
change in apparent diffusion coefficient (delta ADC).
Results Using cautious criteria, CRE andMR imaging with DWI (reader 1/reader 2) have comparable high specificity (83% and 89%/
95%, respectively), whereas MR imaging without DWI showed significantly lower specificity (63%/53%) than CRE. Using strict
criteria, CRE and MR imaging with DWI both showed very high specificity (99% and 92%/95%, respectively), whereas MR imaging
without DWI showed significantly lower specificity (89%/77%) than CRE. All sensitivities were not significantly different. Addition of
MR imagingwithDWI toCREhas statistically significant incremental value in identifying residual tumour (reader 1: estimate, 1.06; p=
0.001) (reader 2: estimate, 0.62; p= 0.02). Adding the deltaADCdid not have significant incremental value in detecting residual tumour.
Conclusions DWI significantly increases the specificity of MR imaging in the detection of local residual tumour. Furthermore,
MR imaging with DWI has significant incremental diagnostic value over CRE, whereas adding the delta ADC has no incremental
diagnostic value.
Key Points
• If MR imaging is used for response evaluation, DWI should be incorporated
• MR imaging with DWI has diagnostic value comparable/complementary to clinical response evaluation
• Inter-reader agreement is moderate to fair for two experienced radiologist readers
• Quantitative measurements of ADC early post-therapy have limited diagnostic value
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Introduction
Cervical cancer represents a major health burden, with for
instance around 12,000 newly diagnosed patients in the
USA each year (US Cancer Statistics Working Group 2016).
The standard treatment for locally advanced cervical cancer is
external beam radiotherapy with image-guided adaptive
brachytherapy [1, 2] and concurrent chemotherapy [3, 4] or
hyperthermia [5]. More than 90% of patients show complete
local response after such treatment [6–8].
To detect local residual tumour at an early time point
(2–3 months after treatment) and allow potentially cura-
tive salvage therapy, response assessment after radio-
therapy is uniformly recommended [9–11]. Although
the effect of salvage surgery on survival is not well
studied, retrospective studies suggest that early detection
of local residual disease in asymptomatic women may
offer survival benefit [12, 13]. Moreover, salvage hys-
terectomy for local disease at a later, i.e. symptomatic,
stage has high complication rates or is not feasible be-
cause of irresectable disease [14]. Therefore, a well-
founded diagnosis of local residual tumour shortly after
completing radiotherapy would be helpful in the timely
selection of women for salvage surgery, and might con-
tribute to enhanced survival. Secondly, the patient with
residual disease not suitable for salvage surgery might
be quickly informed about her unfortunate prognosis in
a timely manner.
In most centres, response assessment is performed via clin-
ical response examination (CRE) at 2–3 months after radio-
therapy [1, 2]. This pelvic exam can be unsatisfactory because
of the altered anatomy after radiotherapy (no cervix, stricture
of the vagina, fibrosis) and the discomfort and pain experi-
enced by patients. Subsequently an examination under anaes-
thesia may be necessary.
A seemingly attractive alternative after completing radio-
therapy therefore is imaging, either with PET CT scanning or
magnetic resonance (MR) imaging.
The use of PET-CT has recently been advised for response
evaluation according to the National Comprehensive Cancer
Network (NCCN 2017). In the earlier European Society of
Medical Oncology guideline PET-CT is not incorporated for
response evaluation [15]. As far as we know, no data exists on
its diagnostic value in the first response evaluation. For this
reason we do not use PET-CT in our departments. Further
prospective studies are needed to ensure its diagnostic value.
MR imaging has so far been unable to fulfil the need
to detect residual disease after radiation because of a
false positive rate of up to 45% [16, 17] that is mainly
attributable to difficulties in differentiating residual tu-
mour from local oedema. The development of MR im-
aging with diffusion-weighted imaging (DWI) has led to
investigations of its potential in differentiating high cel-
lular matrix (as seen in tumour) from low cellular ma-
trix (as seen in oedema). Several studies have shown
promising results in identifying local residual tumour
after radiotherapy, for instance in rectal cancer and
breast cancer [18–21]. In 2015, a systematic review de-
scribed the additional value of DWI in monitoring treat-
ment response in patients undergoing chemoradiotherapy
for locally advanced uterine cervical cancer [21]. A
greater increase of the apparent diffusion coefficient
(ADC) was seen after treatment versus before treatment
if response was complete. However, data were not ex-
ternally validated. Moreover, reference standard was
mostly based on MR imaging findings. To the best of
our knowledge, only two recent studies have evaluated
the accuracy of MR imaging with DWI [22, 23]. The
first study was a single-centre study of retrospective
design, while the second study involved retrospective
analysis without standard use of pathologic evidence
as a reference standard, instead also using radiological
follow-up.
The primary aim of our study was to perform a multicentre
study of the incremental value of MR imaging with DWI
compared to standard MR imaging in the first response eval-
uation after radiotherapy for cervical cancer. A secondary aim
was to evaluate the additional value of MR imaging with or
without DWI in comparison to CRE. Histopathology or a
minimal follow-up of 1 year was used as reference standard.
Materials and methods
Study design and patients
This prospective study was approved by the institutional re-
view board in the three participating university hospitals
(Erasmus University Medical Centre Rotterdam, Academic
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Medical Centre Amsterdam, University Hospitals Leuven)
and written informed consent was obtained from all patients.
The study was registered under trial ID (NTR3345). Study
reporting was in accordance with the Standards for Reporting
Diagnostic Accuracy Studies (STARD 2015).
From March 2011 to April 2015, all patients of 18 years
and older with a primary tumour of the cervix and scheduled
for radiation therapy with curative intent were included.
Pregnant women, women with a contraindication for general
anaesthesia or MRI and women with cognitive deficits were
excluded.
Clinical response examination
CRE was based on a pelvic exam, performed by a staff or
fellow gynaecological oncologist. CRE included visualisation
of the cervix and vagina with a speculum and bimanual
rectovaginal palpation.
Treatment response was scored prospectively as either sus-
picious or not suspicious for residual tumour and was labelled
‘indeterminate’ when patients were too difficult to evaluate,
when findings were equivocal, or when the patient refused
evaluation at the outpatient clinic. The reader extracting the
indeterminate results retrospectively from the medical records
was blinded to the MR imaging findings.
For CRE, sensitivity and specificity were calculated on the
basis of cautious criteria (i.e. indeterminate results were clas-
sified as residual tumour) and on strict criteria (i.e. indetermi-
nate results were classified as complete response).
As a result of ethics requirements at one centre, the T2-W
MRI alone was available to the treating clinicians after CRE.
In no patient was the information from DWI used. Where
CRE was negative and MR imaging findings without DWI
were suspicious for residual tumour, a subsequent clinical ex-
amination under anaesthesia was performed or a closer
follow-up proposed. Although this could induce verification
bias in some cases, it probably had no influence on the refer-
ence standard result, since residual tumour would only be
detected earlier than during follow-up. In no patient was the
information of DWI used.
MR imaging
In each participating centre, at a predefined time point around 2
months after treatment, imaging was performed on a state-of-
the-art 3.0-Tesla MR scanner. In each participating centre, pre-
treatment MR imaging was done within 4 weeks of treatment
start and response MR imaging was planned 6–8 weeks after
finalising radiotherapy. The protocol differed slightly between
different vendors (Philips, Best, the Netherlands and General
Electrics, Milwaukee, WI). Protocols can be found in Table 1.
Imaging was performed before start of treatment and after com-
pleting radiotherapy. One institution used intravaginal gel.
MR image analysis
MR imaging was reviewed independently by two experi-
enced readers (reader 1, an abdominal radiologist for more
than 14 years; reader 2, an abdominal radiologist for more
than 10 years). Both readers were blinded to clinical and
pathological results. The pre-therapy images were at the
readers’ disposal to correlate the location of the primary
tumour, similar to the evaluation process performed in dai-
ly clinical practice.
Evaluation was based on first (1) T2-weighted MR images
(T2-WI) in three directions, then (2) T2-WI with DWI, and
finally (3) the change in apparent diffusion coefficient
(δADC) between post-therapy and pre-therapy.
The post-therapy DWI was analysed first together with the
information from before treatment. This is very helpful for
localisation. The rationale for this was to imitate clinical rou-
tine asmuch as possible.We assume that in clinical practice all
patients have an initial scan before therapy.
The criterion for residual tumour based on T2-WI was a
solid residual mass with intermediate signal intensity. The
criterion for residual tumour based on DWI was b1000
hyperintensity, not attributable to T2 shine-through, at the lo-
cation of the primary tumour as correlated to the T2-WI. For
the DWI evaluation, qualitative interpretation of the ADC
map provided additional information when deemed necessary
by the reader. For example, if the lesion had high intensity on
DWI with a corresponding low value on the ADC map (based
on qualitative interpretation without quantitative measure-
ment), it was interpreted as tumour. In the third evaluation,
based on objective quantitative measurement of the ADC
values, the criterion for residual tumour was δADC ≤ 31.0 ×
10−4. As published earlier, a δADC ≥ 62.0 × 10−4 was con-
sidered a complete response [21].
The ADC was measured by circular region of interest
(ROI) as large as possible within the solid tumour on the
ADC maps on the largest axial tumour slice. Special atten-
tion was paid to avoid the areas of focal signal intensity
changes, susceptibility artefacts and necrosis. If during re-
sponse evaluation no tumour was visible, the location of
the tumour on the pre-therapy scan was used for ROI mea-
surements. While the justification for this approach is de-
batable, in most previous studies on cervical carcinoma
quantification has been performed in the same way, mak-
ing it at least comparable [21].
The radiological response of the primary tumour was
scored using a five-point score (1 = definite complete re-
sponse, 2 = probable complete response, 3 = indeterminate
result, 4 = probable residual tumour, 5 = definite residual
tumour). As for CRE, sensitivity and specificity were calcu-
lated on the basis of cautious criteria (i.e. indeterminate results
were classified as residual tumour) and on strict criteria (i.e.
indeterminate results were classified as complete response).
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Reference standard
All patients underwent a pelvic examination after radiotherapy
and subsequently every 3 months, for at least a year. It is
assumed that most small, clinically overt, residual tumours
would become obvious within this follow-up period, although
some recurrences can occur up to 3 years after therapy.
Histopathological evaluation served as the reference standard
in case of positive results. A recurrence-free follow-up period
of at least 1 year was considered a surrogate reference standard
for a complete local response. Routine histopathology in all
cases would have added the burden of an additional examina-
tion under anaesthetic (EUA) and was deemed unacceptable.
Statistical analysis
For interpretation of T2-weighted images with or without
DWI, interobserver agreement on the five-point scale was
calculated via Cohen’s kappa, using a weighted method based
on the squared distance from the diagonal. Kappa values of 0–
0.20 were interpreted as poor agreement, 0.21–0.40 as fair,
0.41–0.60 as moderate, 0.61–0.80 as good and 0.81–1 as ex-
cellent agreement.
A logistic regression model was constructed first with CRE
only (model 1), and subsequently by adding T2-WI (model 2),
T2-WI with DWI (model 3) and δADC (model 4) as indepen-
dent variables for identification of residual tumour (dependent
variable) by the two radiology readers. Our sample size calcula-
tion was based on optimising specificity, in order to decrease the
false positive rate due to local oedema. We chose an alpha value
of 0.05 and estimated the prevalence of residual tumour at 10%.
To demonstrate a significant difference in the expected specific-
ity of 0.70 compared to the previously found specificity of 0.55,
with a power of 0.80, would require 83 patients without residual
tumour. With 10% expected to have residual tumour and 90% a
complete response, 92 patients were required. Allowing for 10%
loss to follow-up would mean that we needed 101 patients.
Results
Patient and response characteristics
A total of 133 patients were eligible; 26 patients were exclud-
ed [refusal of further inclusion (n = 17), change of therapy (n =
5), further therapy elsewhere (n = 2), death during therapy (n =
1), claustrophobia in MR scanner (n = 1)], leaving 107 pa-
tients for analyses. Baseline demographics and clinical char-
acteristics are shown in Table 2. The reason for the conserva-
tive treatment of the patient with a FIGO Ia was a relative
contraindication for operation.
A complete response was found in 95 patients, whereas 12
patients (11%) had local residual tumour on biopsy or resec-
tion (see examples in Figs. 1 and 2). The range of the tumour
maximal diameter was between 1 mm and 62 mm, with a
mean of 24 mm and a standard deviation of 21 mm. The mean
time interval between the end of radiotherapy and response
evaluation was 51 days (95% CI 48–53) for CRE and 42 days
(95%CI 40–44) forMRI. Follow-up duration in patients with-
out recurrence was between 1.1 and 5.2 years.
Interobserver agreement
Interobserver agreement on a five-point scale was fair (0.32) for
interpretation of T2-WI and moderate (0.46) for the interpreta-
tion of T2-WI +DWI.When the five-point scale was converted
Table 1 The protocol differed
slightly between the different
vendors (Philips Healthcare, Best,
the Netherlands and General
Electrics, Milwaukee, Wis).
Imaging was performed before
the start of treatment and after
completing radiotherapy. One
institution used intravaginal gel
(Fig. 2b)
Scanner (3 Tesla) GE scanner (centre 1) Philips scanner
(centres 2 and 3)
Patients included 85 22
T2-weighting (2D) TR/TE (ms/ms) 9436/81 4571/80
Scan plane 3 directions 3 directions
Flip angle (grades) 120 90
Matrix size 320 × 320 344× 285
Bandwidth (kHz) 125 125
Field view 24 24
Number of excitations 2 1
Slice thickness (mm) 4 4
Gap 0.4 0.4
DWI (2D) Gradient 3 directions 3 directions
Scan plane Axial Axial
b values 0–50–100–500–750–1000 0–50–100–500–750–1000
Bandwidth (kHz) 125 125
Slice thickness (mm) 4 4
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to a three-point scale, interobserver agreement was fair for in-
terpretation of T2-WI (0.26) and T2-WI + DWI (0.39).
Diagnostic performance of CRE and MR imaging
Diagnostic performance in the interpretation of CRE, T2-WI
and T2-WI + DWI are shown in Table 3. Almost all
specificities of T2-WI with DWI (asterisk) were significantly
higher compared to T2-WI. The sensitivities of T2-WI with
DWI did not differ significantly compared to T2-WI.
Compared to CRE, MR imaging had significantly lower
specificities in all situations (bold), and sensitivities and spec-
ificities of T2-WI with DWI were not significantly different.
Only for reader 1 in the strict setting was sensitivity signifi-
cantly higher than that for CRE (bold).
Logistic regression analyses of the effect of adding dif-
ferent MR imaging protocols to the CRE are shown in
Table 4. The model with only CRE (model 1) demonstrated
the value of CRE (β = 1.74, p = 0.0006) in identifying
residual tumour. Model 2 demonstrated the significant
added value of T2-WI in addition to CRE (reader 1: β =
0.77, p = 0.009) (reader 2: β = 0.88, p = 0.01). Adding
DWI to the T2-WI protocol (model 3) demonstrated the
significant added value of DWI (reader 1: β = 1.06, p =
0.001) (reader 2: β = 0.62, p = 0.02) and showed that T2-
WI with DWI can replace CRE. The addition of the δADC
(model 4) had no added value for either reader.
Difference in ADC between pre-treatment
and response MRI (δADC)
We compared δADC values for patients with a complete re-
sponse and patients with residual tumour for both readers.
According to the scatterplot depicting the δADC values for
both readers (Fig. 3), the values of the two readers were not
comparable.
Further ROC analysis demonstrated moderate discrimina-
tion (Fig. 4): using the aforementioned cut-offs of ≥ 62 × 10−4
for complete response and ≤ 31 × 10−4 for residual tumour, the
readers achieved only intermediate sensitivities and
specificities.
Fig. 1 This 50-year-old patient was clinically evaluated as non-suspect
61 days after radiation therapy. T2-weighted imaging (a, arrow) showed
an indeterminate aspect of the cervix and was therefore supplemented
with true cut biopsy under anaesthesia. This confirmed residual disease
on histopathology. At the end of the study diffusion-weighted imaging
(DWI) was analysed, blinded for the histopathology result. This showed
(b, arrow) a clear hyperintense region. Visual ADC information (low
intensity) was used to differentiate from mucosal oedema (c, arrow),
leading to the diagnosis of residual tumour by both readers. The δADC
was only suspect for local residue for reader 2 (δADC, reader 1: 52 × 10−4
and reader 2: 29 × 10−4) on the basis of aforementioned cut-off of 31 ×
10−4
Table 2 Patient characteristics
Patient characteristics
Total number of patients 107
Age (median, range) 49 (27–84)
Tumour stage
FIGO Number %
IA 1 1
IB1 4 4
IB2 13 12
IIA 5 5
IIB 67 63
IIIA 3 3
IIIB 10 9
IVA 4 4
Histologic subtype
Squamous cell carcinoma 87 81
Adenocarcinoma 13 12
Other 7 7
Treatment
Chemoradiation 80 75
Radiotherapy + hyperthermia 27 25
(± Induction chemotherapy)
Brachytherapy 105 98
No brachytherapy 2 2
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Fig. 2 A 30-year-old patient with
a normal post-therapeutic clinical
examination. T2-weighted MR
imaging (a, b arrow) showed an
infracentimetric suspicious region
centrally in the cervix. Local
follow-up during 1 year remained
normal. Diffusion-weighted im-
aging (DWI, c arrow) was not
suspect for both readers. The
ADC map (d arrow) was hyper-
intense (ADC, reader 1: 132 ×
10−4 mm2/s and reader 2: 125 ×
10−4 mm2/s), confirming the
presence of fluid rather than tu-
mour. The delta ADC was not
suspect for readers (δADC, reader
1: 63 × 10−4 and reader 2: 52 ×
10−4) on the basis of aforemen-
tioned cut-off of 31 × 10−4. Note
the use of intravaginal gel in order
to expand the vagina on b (white
star)
Table 3 CRE and MR imaging findings of local residual tumour with
corresponding diagnostic values using cautious and strict criteria. Using
cautious criteria indeterminate findings were labeled as suspicious for
residual tumour and using strict criteria indeterminate findings were
labeled as not suspicious for residual tumour. CRE clinical response
examination, T2-WI T2-weighted MR imaging, T2-WI + DWI T2-
weighted imaging + diffusion-weighted imaging, CI 95% confidence
interval. Asterisk refers to the outcome which was significantly different
on T2-WI + DWI compared to T2-WI. Bold highlights figures which
were significantly different on T2-WI or T2-WI + DWI compared to CRE
Cautions criteria Strict criteria
Sensitivity Specificity Sensitivity Specificity
CRE 58% (7/12) 83% (79/95) 25% (3/12) 99% (94/95)
(CI 32–82) (CI 76–89) (CI 7–53) (CI 95–100)
T2-WI Reader 1 67% (8/12) 63% (60/95) 58% (7/12) 89% (85/95)
(CI 39–88) (CI 54–71) (CI 32–82) (CI 83–94)
Reader 2 83% (10/12) 53% (50/95) 75% (9/12) 77% (73/95)
(CI 56–97) (CI 44–61) (CI 47–93) (CI 69–84)
T2-WI+DWI Reader 1 83% (10/12) 89% (85/95)* 83% (10/12) 92% (87/95)
(CI 56–97) (CI 83–94) (CI 56–97) (CI 85–96)
Reader 2 50% (6/12) 95% (90/95)* 50% (6/12) 95% (90/95)*
(CI 25–75) (CI 89–98) (CI 25–75) (CI 89–98)
*T2-WI with DWI statistically significantly higher compared to T2-WI
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Discussion
In this prospective multicentre study, we found that DWI sig-
nificantly increases the specificity of MR imaging in the de-
tection of residual local tumour compared to T2W imaging
alone during response evaluation of cervical carcinoma fol-
lowing radiotherapy. MR imaging with DWI also showed
significant incremental value over CRE.
In a situationwhereMR imaging is appended to the treatment
response evaluation, DWI information should always be added
to reduce the chance of incorrectly declaring an unfavourable
outcome, i.e. presumed residual tumour in cases with a complete
response. This is in line with our hypothesis, since the presence
Table 4 Logistic regression
analyses of addition of various
MR imaging protocols to the
CRE. Parameters with significant
p values are shown in bold. CRE
clinical response examination,
T2-WI T2-weighted MR
imaging, T2-WI + DWI T2-
weighted imaging + diffusion-
weighted imaging, δADC is the
difference between the
pretreatment ADC and the post-
treatment ADC,ADC apparent
diffusion coefficient, estim.
estimate, std err. standard error
Reader 1 Reader 2
Model 1 Model 1
Estim. Std. err. p-value Estim. Std. err. p-value
Intercept -2.84 0.46 p<0.0001 Intercept -2.84 0.46 p<0.0001
CRE 1.74 0.50 0.0006 CRE 1.74 0.51 0.0006
Model 2 Model 2
Estim. Std. err. p-value Estim. Std. err. p-value
Intercept -4.61 0.95 p<0.0001 Intercept -5.52 1.30 p<0.0001
CRE 1.22 0.58 0.03 CRE 1.47 0.57 0.01
MRimaging 0.77 0.30 0.009 MRimaging 0.88 0.35 0.01
Model 3 Model 3
Estim. Std. err. p-value Estim. Std. err. p-value
Intercept -5.43 1.17 p<0.0001 Intercept -5.36 1.26 p<0.0001
CRE 1.08 0.65 0.09 CRE 1.03 0.66 0.1
MRimaging 0.03 0.40 0.9 MRimaging 0.54 0.38 0.2
MRimaging+DWI 1.06 0.32 0.001 MRimaging+
DWI
0.62 0.26 0.02
Model 4 Model 4
Estim. Std. err. p-value Estim. Std. err. p-value
Intercept -7.09 2.35 0.003 Intercept -5.08 1.48 0.0006
CRE 1.35 0.77 0.07 CRE 0.96 0.69 0.2
MRimaging 0.10 0.41 0.8 MRimaging 0.56 0.39 0.2
MRimaging+DWI 1.29 0.43 0.003 MRimaging+
DWI
0.59 0.29 0.04
δADC 0.01 0.02 0.4 δADC -0.00 0.01 0.7
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Fig. 3 Scatter plot comparing delta ADC values for reader 1 and reader 2
shows the values were not comparable. ADC apparent diffusion
coefficient
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Fig. 4 ROC analysis of change of ADC between pre- and post-treatment
ADC (δADC) for reader 1 (red line) and reader 2 (blue line). Cut-offs for
complete response (≥ 62 × 10−4) and residual tumour (≤ 31 × 10−4) and
their corresponding sensitivities and specificities are shown
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of oedema hampers T2-WI, resulting in misdiagnoses of resid-
ual disease. Oedema is typically seen in the first months after
radiation therapy, at the time when response evaluation is per-
formed to decide on complementary surgery in case of residual
disease. Our finding is also in line with a previous study show-
ing that T2-WI alone resulted in up to 50% false positives [16].
Our findings are in accordance with a recent retrospective
study, where a high specificity (84 %) was found using a
combination of high intensity on T2-WI and high intensity
on DWI [22]. However, that study differed from ours since
their inclusion consisted mainly of lower stages of cervical
carcinomas in a neoadjuvant setting.
To the best of our knowledge, our study is the first to compare
CRE with combined T2-WI and DWI for early response assess-
ment after radiation for cervical carcinoma. One study evaluating
CRE versus conventional MR imaging in the response assess-
ment after radiation therapy reported thatMRI scored significant-
ly worse than CRE,mainly in terms of specificity [16]. However,
as that study did not incorporate DWI, it is difficult to compare
their results with ours. With the current protocol, we found that
MR imaging with DWI significantly improves work-up com-
pared to CRE. It is unlikely that there was bias from the same
clinician doing the clinical assessment as doing the CRE, as these
assessments were done a year apart.
One could argue that as a result of current optimised radia-
tion therapy schemes, including MR imaging or CT-guided
brachytherapy, the percentage of patients with local residual
tumour after radiotherapy treatment for cervical cancer is too
low to justify further protocols such as MR imaging. Distant
recurrence probably has more impact on survival. However, it
remains a fact that only local residual tumour can potentially be
cured, for instance with salvage surgery. Despite the low prev-
alence of local residual tumour without distant metastases, it is
therefore imperative that the patient with residual tumour is
recognised soon after treatment while salvage is still an option.
Logistic regression analysis showed that if both CRE andMR
imaging with DWI are used, only the latter has a significant
impact on identifying local residual tumour. A first option would
be to replace all CRE by MR imaging with DWI. Although
theoretically our data suggest that this would be an acceptable
alternative, in clinical practice clinicians would still prefer to
examine the patient during the first response evaluation, since it
is inexpensive. Moreover, very small superficial and mucosal
based residual tumours will probably remain undetected with
MR imaging. A second option could be to useMR imaging with
DWI in case CRE is difficult to perform or when the patient is
uncooperative. A third option is to perform both CRE and MR
imaging during the first response evaluation in all cases. The last
two options have four clear advantages. First, theMR images can
be reviewed at a later time point and can be discussed with
colleagues, which is impossible with CRE. CRE also depends
on the experience of the physician. A second advantage is that
these initialMRI data are available during follow-up, particularly
in cases in which new (clinical) problems and queries arise. The
third advantage of usingMR imaging is to guide eventual biopsy
more precisely in the deeper cervical regions that are more diffi-
cult to evaluate with CRE. Finally, in the case of proven local
residual tumour, MR imaging is usually better than CRE in iden-
tifying local parametrial or pelvic wall invasion, which could
make salvage hysterectomy unfeasible, as was shown in an ear-
lier meta-analysis by our study group [24].
A final option is to add MR imaging depending on the prob-
ability of local residual tumour and distal tumour recurrence.
Higher stages of cervical carcinoma, especially those with possi-
ble lymphadenopathy outside the radiation field, would have less
benefit of salvage surgery, making MRI with DWI less useful.
Quantitative evaluation of the ADC post-therapy versus pre-
therapy was less helpful in our study, in contrast to findings re-
ported in an earlier systematic review [21]. The overall absolute
cut-offs found for residual tumour versus absence thereof were
not reproduced in ourmulticentre setting. The use of differentMR
systems may have possibly played a role in our varied results.
Indeed, a previous study has shown that absoluteADCvalues can
be vendor-specific, depending on the region scanned in the upper
abdomen [25]. As far as we know, the reproducibility of ADC
values in the cervical regions across different scanners has not
been fully studied. However, in terms of our findings, it is debat-
able whether the use of different vendors explains the differences,
since only two protocols were used, with very similar sequence
details and b values. On the basis of our findings, we conclude
that measurement of ADC differences is time-consuming and is
not particularly helpful, even more so because our logistic regres-
sion model showed no influence of these data on the final diag-
nosis of local residual tumour for either radiologist reader.
There are some drawbacks to our study. The inter-reader agree-
ment was only moderate to fair for MR imaging evaluation,
which might suggest that the results are not fully reproducible.
This could be an important obstacle to further implementation of
this technique. However, the readers took different approaches to
image evaluation despite having received the same predetermined
interpretation criteria as mentioned earlier. Reader 1 was more
cautious and evaluated indeterminate lesions more often as resid-
ual tumour, thereby increasing sensitivity, while reader 2 used
more strict criteria for diagnosing residual tumour, i.e. he evaluat-
ed indeterminate lesions more often as a complete response.
Furthermore, reader 1 had more experience with DWI in the
pelvis (10 years versus 6 years), which could also explain his
higher sensitivity (although not significantly higher). Further stud-
ies should be performed to establish the reproducibility of DWI
for identifying residual cervical cancer post radiotherapy.
The results concerning sensitivity were not significantly
different across protocols. As a result of the low prevalence
of residual disease, our study would have required over 240
patients to allow conclusions about sensitivity. For reasons of
feasibility we powered the study to demonstrate an increase in
specificity by adding DWI to the T2-weighted imaging.
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According to the most recent guidelines, treatment evaluation
should be done around 3 months after the end of treatment [15].
We decided to perform the MRI some weeks earlier, mainly
because we wanted to diagnose residual tumour as soon as pos-
sible, in order to enhance the possibilities of local salvage. Too
soon after treatment though, the interpretation could be hampered
by oedema. However, we prioritised early detection, as the use of
DWI for identifying tumour is not compromised by local oedema.
In conclusion, the addition of DWI to the standard MRI
protocol significantly improves the value of MR imaging.
Furthermore, MR imaging with DWI has significant incre-
mental value relative to CRE in finding residual cervical tu-
mour after radiation therapy, and could possibly replace the
latter in situations where CRE is less practical. ADC has no
incremental diagnostic value.
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